

Ampulla of Vater

**Protocol applies to all intra-ampullary, peri-ampullary,
and mixed intra- and peri-ampullary carcinomas.**

*Protocol revision date: January 2005
Based on AJCC/UICC TNM, 6th edition*

Procedures

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Ampullectomy**
- **Pancreaticoduodenectomy (Whipple Resection)**

Author

Carolyn C. Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada
For the Members of the Cancer Committee, College of American Pathologists

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Summary of Changes to Checklist(s)

Protocol revision date: January 2005

The following changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Ampullectomy Checklist

Microscopic

Tumor Size: An optional data element was added to record two additional dimensions in addition to the greatest dimension, as shown below

Tumor Size

Greatest dimension: ____ cm

*Additional dimensions: ____ x ____ cm

____ Cannot be determined (see Comment)

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

AMPULLA OF VATER: Ampullectomy

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Tumor Site**

- Intra-ampullary
 Peri-ampullary
 Junction of ampullary and duodenal mucosa
 Not specified

MICROSCOPIC**Histologic Type**

- Adenocarcinoma (not otherwise characterized)
 Papillary adenocarcinoma
 Adenocarcinoma, intestinal type
 Adenocarcinoma, gastric foveolar type
 Mucinous adenocarcinoma
 Clear cell adenocarcinoma
 Signet-ring cell carcinoma
 Adenosquamous carcinoma
 Other (specify): _____
 Carcinoma, type cannot be determined

Histologic Grade

- Not applicable (histologic type not usually graded)
 GX: Cannot be assessed
 G1: Well differentiated
 G2: Moderately differentiated
 G3: Poorly differentiated
 G4: Undifferentiated
 Other (specify): _____

4

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Tumor Size

Greatest dimension: ___ cm

*Additional dimensions: ___ x ___ cm

___ Cannot be determined (see Comment)

Pathologic Staging (pTNM)Primary Tumor (pT)

___ pTis: Carcinoma in situ

___ pT1: Tumor limited to ampulla of Vater or sphincter of Oddi

___ pT2: Tumor invades duodenal wall

Margins (check all that apply)

___ Not applicable

___ Cannot be assessed

___ Uninvolved by invasive carcinoma

Specify distance of invasive carcinoma to closest margin: ___ mm

___ Uninvolved by carcinoma in situ/adenoma

___ Involved by carcinoma in situ/adenoma

___ Involved by invasive carcinoma

***Additional Pathologic Findings (check all that apply)**

* ___ None identified

* ___ Dysplasia/adenoma

* ___ Ampullitis

* ___ Adenomyosis

* ___ Other (specify): _____

***Comment(s)**

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005
Applies to invasive carcinomas only
Based on AJCC/UICC TNM, 6th edition*

**AMPULLA OF VATER: Pancreaticoduodenectomy
(Whipple Resection)**

Patient name:

Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC**Specimen Type**

- Pancreaticoduodenectomy
 Pancreaticoduodenectomy (pylorus sparing)
 Other (specify): _____
 Not specified

Tumor Site (check all that apply)

- Intra-ampullary
 Peri-ampullary
 Junction of ampullary and duodenal mucosa
 Not specified

Tumor Size

Greatest dimension: ___ cm

*Additional dimensions: ___ x ___ cm

 Cannot be determined (see Comment)**MICROSCOPIC****Histologic Type**

- Adenocarcinoma (not otherwise characterized)
 Papillary adenocarcinoma
 Adenocarcinoma, intestinal type
 Adenocarcinoma, gastric foveolar type
 Mucinous adenocarcinoma
 Clear cell adenocarcinoma
 Signet-ring cell carcinoma
 Adenosquamous carcinoma
 Other (specify): _____
 Carcinoma, type cannot be determined

6

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Histologic Grade

- Not applicable
 GX: Cannot be assessed
 G1: Well differentiated
 G2: Moderately differentiated
 G3: Poorly differentiated
 G4: Undifferentiated
 Other (specify): _____

Pathologic Staging (pTNM)Primary Tumor (pT)

- pTX: Cannot be assessed
 pT0: No evidence of primary tumor
 pTis: Carcinoma in situ
 pT1: Tumor limited to ampulla of Vater or sphincter of Oddi
 pT2: Tumor invades duodenal wall
 pT3: Tumor invades pancreas
 pT4: Tumor invades peripancreatic soft tissues or other adjacent organs or structures

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
 pN0: No regional lymph node metastasis
 pN1: Regional lymph node metastasis
 Specify: Number examined: ____
 Number involved: ____

Distant Metastasis (pM)

- pMX: Cannot be assessed
 pM1: Distant metastasis
 *Specify site(s), if known: _____

Margins (check all that apply)

- Cannot be assessed
 Margins uninvolved by invasive carcinoma
 Distance of invasive carcinoma from closest margin: ____ mm
 Specify margin (if possible): _____
 Carcinoma in situ absent at pancreatic duct margin
 Carcinoma in situ present at pancreatic duct margin
 Carcinoma in situ absent at common bile duct margin
 Carcinoma in situ present at common bile duct margin
 Margins involved by invasive carcinoma
 Specify margin(s) (if possible): _____
 Not applicable

* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

***Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- * Absent
- * Present
- * Indeterminate

***Perineural Invasion**

- * Absent
- * Present

***Additional Pathologic Findings (check all that apply)**

- * None identified
- * Dysplasia/adenoma
- * Ampullitis
- * Adenomyosis
- * Chronic pancreatitis
- * Acute pancreatitis
- * Gastritis
- * Other (specify): _____

***Comment(s)**

8 * Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.